Summary:
This open-label study is being conducted to evaluate the safety, tolerability, and efficacy of the concomitant use of ubrogepant for the acute treatment of breakthrough migraine headache in subjects taking atogepant once daily for the preventive treatment of episodic migraines.
Participants must be aged 18 to 80 years old inclusive and have a history of migraine headaches for at least one year. Participants age of migraine onset must be < 50 years and Participants must have a history of 4 to 14 migraine days per month.
Qualified Participants May Receive:
If you qualify, you may receive investigational medication and study-related procedures from a local doctor. Reimbursement for time and travel related to study participation may be provided.